Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The central hypothesis of this study is that TAVR leads to platelet deposition and
inflammatory cell activation that can be attenuated by the potent anti-platelet and/or
pleiotropic effects of ticagrelor.
This single center, prospective randomized trial addresses the following specific aims:
1. To determine whether high-potency ADP receptor blockade reduces measures of platelet
activation in patients after TAVR.
2. To determine whether high-potency ADP receptor blockade mitigates the pro-thrombotic
inflammatory response observed after TAVR.